2017 Key Sessions and Topics

  • Oot.14.2017 (Friday)

Hosted by Co-Organizers

  • Fudan University Zhongshan Hospital
  • China Health Promotion Foundation
  • Shanghai Respiratory Research Institute(SRRI)
  • Institute of Respiratory Diseases, Fudan University

International Society of Respiratory Diseasesh (TRM)

International Society of Respiratory Diseasesh(TRM) is a truly international, peer-reviewed journal devoted to the publication of articles on outstanding work with translational potentials between basic research and clinical application, on pathology, immunology and 'omics science to understanding respiratory disease. TRM provides a forum for exchange of ideas on potential molecular and cellular mechanisms of respiratory diseases. The journal aims to play an important, critical, and recognized role in the understanding of human respiratory diseases and improvement of the prognosis of patients.

Topics include:

  1. Respiratory pathology
  2. Respiratory omics science and bioinformatics
  3. Tissue imaging and informatics in respiratory diseases
  4. Respiratory disease-specific biomarkers and clinical significance
  5. Drug discovery and development for respiratory diseases

Open access

All articles published by Translational Respiratory Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Translational Respiratory Medicine are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the SpringerOpen copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Translational Respiratory Medicine therefore levies an article-processing charge of £1155/$1880/€1390 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.

Indexing services

SpringerOpen is working closely with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Translational Respiratory Medicine will be available.

Publication and peer review process

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My International Society of Respiratory Diseasesh, a personalized section of the site.

Portability of peer review

In order to support efficient and thorough peer review, we aim to reduce the number of times a manuscript is re-reviewed after rejection from International Society of Respiratory Diseasesh, thereby speeding up the publication process and reducing the burden on peer reviewers. Therefore, please note that, if a manuscript is not accepted for publication in Translational Respiratory Medicine and the authors choose to submit a revised version to another SpringerOpen journal, we will pass the reviews on to the other journal's editors at the authors' request. We will reveal the reviewers' names to the handling editor for editorial purposes unless reviewers let us know when they return their report that they do not wish us to share their report with another SpringerOpen journal.

Editorial policies

Any manuscript, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.

Editorial standards

SpringerOpen is a member of the Committee on Publication Ethics (COPE) and endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions. In order to safeguard the quality of SpringerOpen journal publications, Springer has developed a policy on Publishing Integrity which is in line with the philosophy of COPE.

We follow the principle that we have a prime duty to maintain the integrity of the scientific record. Springer’s Policy on Publishing Integrity addresses:
  • Clear definitions of what violation of Publishing Integrity is.
  • A manual on how to identify such a violation (in the document referred to as an Act of Misconduct).
  • Clear (COPE) examples of what such an Act of Misconduct looks like in practice.
  • Clearly defined actions which have to be undertaken by the Editor and Springer when such an Act is a clearly proven fact.
  • Q & A – a useful list of Questions and Answers on the definition of Publishing Integrity.

Please find the full document of Springer's Policy on Publishing Integrity here.

Ethical guidelines

Submission of a manuscript to Translational Respiratory Medicine implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.

For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available if requested by the editorial staff.

International Society of Respiratory Diseasesh's publisher, Springer, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the publisher if required, will work with authors to ensure an appropriate outcome is reached.

The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.

Standards of reporting

International Society of Respiratory Diseasesh supports initiatives aimed at improving the reporting of biomedical research. We recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies. .
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications.

International Society of Respiratory Diseasesh also supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (http://www.icmje.org/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the target="_blank"WHO International Clinical Trials Registry Platform including the ISRCTN register administered by Current Controlled Trials, part of BioMed Central Group.

The trial registration number should be included as the last line of the manuscript abstract, and where possible the trial record’s persistent identifier should be cited in the manuscript’s reference list.

Data and materials release

Submission of a manuscript to Translational Respiratory Medicine implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.

Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.

For more details, please visit http://www.transrespmed.com/


Honorary Chairman
Nanshan Zhong(Guangzhou, China)
Academician, China Academy of Engineering
Chairman, Guangzhou Institute of Respiratory Diseases
Director, State Key Laboratory of Respiratory Diseases
Chunxue Bai
Chairman, Shanghai Respiratory Research Institute
Chairman, Department of Pulmonary Medicine
Zhongshan Hospital, Fudan University
Scientific Committee Chairman
Xiangdong Wang(Sweden)
Director of Biomedical Research Center, Zhongshan Hospital, Fudan University
JCBi Chief Editor
Thomas W.Ferkol(USA) President, American Thoracic Society
General Secretary
Yuanlin Song(Shanghai, China)
Researcher, Zhongshan Hospital, Fudan University
Distinguished Professor, Shanghai Municipal Education Commission
Jian Zhou(Shanghai, China) Shanghai Respiratory Research Institute, Young researcher